FDA Approves Lumateperone For Prevention of Relapse in Schizophrenia

The FDA approved a supplemental new drug application for lumateperone (Caplyta) for the prevention of relapse in adults living with schizophrenia. This approval, announced by Johnson & Johnson, is supported by robust long-term data demonstrating that the therapy significantly reduces the risk of symptomatic relapse, which remains one of the most significant challenges in managing this chronic condition. For pharmacists and clinicians, this update provides a critical tool for maintaining long-term stability in a patient population where roughly 40% of individuals do not receive adequate care.¹

“Relapse can be one of the most disruptive aspects of schizophrenia, often undoing hard-won progress and increasing the risk of hospitalization,” Christoph U. Correll, MD, clinical professor of psychiatry at the Zucker School of Medicine at Hofstra/Northwell, New York, said in a news release. “These phase 3 results—showing significantly longer time to relapse with 84% remaining relapse-free over 6 months—provide clinicians with another tool that can offer long-term stability for people living with schizophrenia.”

About The Approval

The approval was primarily driven by results from Study 304, a phase 3, multicenter, double-blind, randomized withdrawal trial. During the 26-week double-blind treatment period, patients receiving 42 mg of lumateperone once daily experienced a 63% lower risk of relapse compared to the placebo group. The data revealed that 84% of patients remained relapse-free over the six-month period. Additionally, the therapy significantly delayed the time to all-cause treatment discontinuation, addressing a major hurdle in schizophrenia management where approximately 80% of patients who stop medication after an acute episode experience a relapse within one year.^1,2

From a clinical pharmacy perspective, the metabolic and safety profile of lumateperone continues to be a defining characteristic of the treatment. Unlike many other atypical antipsychotics, lumateperone showed no clinically relevant increases in prolactin or cardiometabolic parameters during the study. Long-term data from a 12-month open-label extension study even showed a mean weight loss of 2.05 kg (4.52 lbs) among participants. The safety profile remained consistent with previous studies, with headache being the most common treatment-related adverse event, occurring in at least 5% of patients at a rate twice that of the placebo.¹

The Pharmacist’s Role

Pharmacists should note that lumateperone is designed for ease of use, as it can be started at its therapeutic dose of 42 mg without the need for titration. However, careful attention to drug interactions is required. The medication should not be used in conjunction with CYP3A4 inducers, and dose reductions are recommended when it is administered alongside strong or moderate CYP3A4 inhibitors. As with other medications in its class, lumateperone carries boxed warnings regarding an increased risk of death in elderly patients with dementia-related psychosis and an increased risk of suicidal thoughts and behaviors in patients 24 years and younger.^1,2

This latest milestone for lumateperone follows its previous approvals for the treatment of bipolar depression and its recent approval as an adjunctive therapy for major depressive disorder. In studies for major depressive disorder, the drug demonstrated a significant improvement in remission rates when combined with traditional antidepressants, nearly doubling the likelihood of remission compared to placebo. By providing sustained relief across multiple neuropsychiatric indications, lumateperone is increasingly positioned as a versatile option for patients seeking recovery and long-term stability.^3,4

“People living with schizophrenia deserve treatment options that help support stability over time, not just symptom control in the short term,” Celine Goldberger, MD, PhD, vice president of global medical affairs, neuroscience, and innovative medicine at Johnson & Johnson, said in the news release.¹ “This label update—backed by long-term phase 3 data demonstrating a significant delay in time to relapse—reinforces our commitment to advancing evidence-based therapies to support each patient’s individual needs, including a proven therapy that supports stability over time.”

REFERENCES

1. FDA approves Caplyta (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia. News release. Johnson and Johnson. April 27, 2026. Accessed April 30, 2026. https://www.jnj.com/media-center/press-releases/fda-approves-caplyta-lumateperone-snda-with-robust-new-data-supporting-reduced-risk-of-relapse-in-schizophrenia

2. Biscaldi L. Lumateperone Demonstrates Efficacy in Reducing Symptomatic Relapse Risk in Schizophrenia. Drug Topics. November 5, 2024. Accessed April 30, 2026. https://www.drugtopics.com/view/lumateperone-demonstrates-efficacy-in-reducing-symptomatic-relapse-risk-in-schizophrenia

3. Gallagher A. FDA Approves Lumateperone as Adjunct Therapy for Major Depressive Disorder. Drug Topics. November 6, 2025. April 30, 3036. https://www.drugtopics.com/view/fda-approves-lumateperone-as-adjunct-therapy-for-major-depressive-disorder

4. Gallagher A. Adjunctive Lumateperone Maintains Remission Rates for Major Depressive Disorder. Drug Topics. January 19, 2026. Accessed April 30, 2026. https://www.drugtopics.com/view/adjunctive-lumateperone-maintains-remission-rates-for-major-depressive-disorder